Entrada Therapeutics, Inc.
TRDA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$4.75
KIRA · Stoqly’s AI analyst, in plain words
- Entrada Therapeutics, Inc. had $25.4M of revenue in fiscal 2025, down 87.9% on the year before.
- Its operating margin was −621.1%, down 643.4 pts: of every 100 in sales, about −621 is left after running the business.
- Entrada Therapeutics, Inc. lost $144M in fiscal 2025.
- Free cash flow was −$130M in fiscal 2025, −509.6% of revenue.
Market cap
$201M
P/E
—
Revenue
$25.4M
Net income
−$144M
Free cash flow
−$130M
Operating margin
−621.1%
Entrada Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−87.9%
No. Sales fell 87.9% last year.
Does it make a profit?
−565.5%
No. It lost money last year.
Does profit turn into cash?
−509.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Entrada Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Entrada Therapeutics, Inc.
- CIK
- 0001689375
Entrada Therapeutics, Inc. · TRDA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $129M | $211M | $25.4M |
| Revenue growth | — | — | — | 63.4% | −87.9% |
| Operating margin | — | — | −2.5% | 22.3% | −621.1% |
| Net income | −$51.2M | −$94.6M | −$6.7M | $65.6M | −$144M |
| Net margin | — | — | −5.2% | 31.1% | −565.5% |
| Diluted EPS | −$8.16 | −$3.02 | −$0.20 | $1.68 | −$3.47 |
| Cash | |||||
| Cash from operations | −$50.9M | −$93.8M | $140M | −$41.6M | −$129M |
| Capital expenditure | $4.6M | $2.9M | $5.6M | $3.2M | $1.0M |
| Free cash flow | −$55.4M | −$96.7M | $134M | −$44.7M | −$130M |
| FCF margin | — | — | 104.0% | −21.2% | −509.6% |
| Share count change | 467.1% | 399.3% | 5.6% | 18.0% | 6.1% |
| Debt and strength | |||||
| Cash and short-term investments | $291M | $45.2M | $67.6M | $101M | $90.4M |
| Shareholders' equity | $299M | $213M | $242M | $429M | $306M |
| Current ratio | 44.5x | 9.6x | 2.3x | 11.1x | 12.5x |
| Returns and quality | |||||
| Return on equity | −39.8% | −37.0% | −2.9% | 19.6% | −39.1% |
| Return on tangible equity | −17.1% | −44.5% | −2.8% | 15.3% | −47.0% |
| Piotroski F-score | — | — | — | 4 | 2 |
| Altman Z'' | 48.2 | 5.5 | 2.7 | 9.4 | 4.2 |
Insiders bought, 12 months
$1.6M
3 insiders
Insiders sold, 12 months
$9.7M
10 insiders
Of sales under plans
13%
$1.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Entrada Therapeutics, Inc. · TRDA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.75 a share, the company is worth $201M.
Source: SEC EDGAR XBRL filings (CIK 0001689375). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.